Detalles de la búsqueda
1.
EphB2-dependent prefrontal cortex activation promotes long-range social approach and partner responsiveness.
Proc Natl Acad Sci U S A
; 120(9): e2219952120, 2023 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36802416
2.
AStruct: detection of allele-specific RNA secondary structure in structuromic probing data.
BMC Bioinformatics
; 25(1): 91, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429654
3.
Advances in detecting N6-methyladenosine modification in circRNAs.
Methods
; 205: 234-246, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35878749
4.
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Cancer Immunol Immunother
; 71(5): 1247-1255, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34647153
5.
Investigation of the Distribution of Thalassemia in Children in Jiangxi Province, the People's Republic of China.
Hemoglobin
; 46(5): 272-276, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36317662
6.
[Chemical constituents from the leaves of Cinnamomum camphora var. linaloolifera and their anti-inflammatory activities].
Zhongguo Zhong Yao Za Zhi
; 46(14): 3592-3598, 2021 Jul.
Artículo
en Zh
| MEDLINE | ID: mdl-34402282
7.
Promoted Interaction of C/EBPα with Demethylated Cxcr3 Gene Promoter Contributes to Neuropathic Pain in Mice.
J Neurosci
; 37(3): 685-700, 2017 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28100749
8.
Spinal CXCL9 and CXCL11 are not involved in neuropathic pain despite an upregulation in the spinal cord following spinal nerve injury.
Mol Pain
; 14: 1744806918777401, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29712506
9.
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Cancer Immunol Immunother
; 71(5): 1257, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34870721
10.
Identification of lncRNA expression profile in the spinal cord of mice following spinal nerve ligation-induced neuropathic pain.
Mol Pain
; 11: 43, 2015 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26184882
11.
Mechanism-based inhibition of CYPs and RMs-induced hepatoxicity by rutaecarpine.
Xenobiotica
; 45(11): 978-89, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26053557
12.
Reactive metabolite activation by CYP2C19-mediated rhein hepatotoxicity.
Xenobiotica
; 45(4): 361-72, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25815638
13.
[Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.
Immunol Res
; 71(2): 213-228, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36434349
14.
LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.
Front Immunol
; 14: 959868, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36798137
15.
Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.
J Cancer Res Clin Oncol
; 149(3): 1103-1113, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35304630
16.
Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.
iScience
; 26(7): 107058, 2023 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37416452
17.
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.
Ther Adv Med Oncol
; 15: 17588359231200463, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37881238
18.
PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Front Immunol
; 13: 1015444, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36248788
19.
A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment.
Thorac Cancer
; 13(11): 1558-1569, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35437945
20.
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
Lung Cancer
; 165: 10-17, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051754